Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Author: Yazbek, R.
Howarth, G.
Abbott, C.
Citation: Trends in Pharmacological Sciences, 2009; 30(11):600-607
Publisher: Elsevier Science London
Issue Date: 2009
ISSN: 0165-6147
Statement of
Roger Yazbeck, Gordon S. Howarth and Catherine A. Abbott
Abstract: Dipeptidyl peptidase (DPP)-4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T-cell proliferation and cytokine production, leading to their investigation in numerous pre-clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4-specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non-specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease.
Keywords: Animals
Drug Delivery Systems
Drug Evaluation, Preclinical
Clinical Trials as Topic
Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Dipeptidyl Peptidase 4
Description: Copyright © 2009 Elsevier Ltd. All rights reserved.
DOI: 10.1016/
Published version:
Appears in Collections:Agriculture, Food and Wine publications
Aurora harvest 5

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.